Document is current
Any future updates will be listed below
-
Authors
Far, Aryana T.
Ayati, Aryan
Guillot, Jordan
Azzam, Shadera
Rudrapatna, Vivek A.
Ge, Jin
-
Funding
Funding for this research was provided by:
University of California, San Francisco-Stanford CERSI/Gilead Postdoctoral Fellowship in Regulatory Science
National Library of Medicine of the National Institutes of Health (K99LM014099)
National Institute of Diabetes and Digestive and Kidney Diseases (K23DK139455)
- License Information
-
More Information
Article History
Received: 19 September 2025
Accepted: 2 November 2025
First Online: 8 November 2025
Declarations
:
: The authors of this manuscript have the following potential conflicts of interest to disclose as described by DDS:—Dr. Jin Ge previously received research support from Merck and Co. He previously served on an advisory board for Gilead Sciences and previously consulted for Astellas Pharmaceuticals/Iota Biosciences and Madrigal Pharmaceuticals.—Dr. Vivek Rudrapatna’s research is partially funded by grants to UCSF from the following for-profit entities: Janssen, Merck, Genentech, Alnylam, Takeda, Mitsubishi Tanabe, Stryker, and Blueprint Medicines. He is also a shareholder in ZebraMD, DataUnite, and Acucare AI. He has received honoraria from Natera and Ironwood Pharmaceuticals.
